Ratings by Jefferies (Roger Song)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 4/17/2024 | Nuvalent | NUVL | New Coverage | Buy (N/A) |
65.28 (63.06) |
-3.4% | Details | |
| 3/20/2024 | Lava Therapeutics NV | LVTX | Maintain | Buy (N/A) |
|
Details | ||
| 3/20/2024 | Tourmaline Bio | TRML | Maintain | Buy (N/A) |
|
Details | ||
| 3/12/2024 | CytomX Therapeutics | CTMX | Maintain | Hold (N/A) |
|
Details | ||
| 3/12/2024 | CytomX Therapeutics | CTMX | Maintain | Hold (N/A) |
|
Details | ||
| 3/7/2024 | Viking Therapeutic | VKTX | New Coverage | Buy (N/A) |
87.90 (64.67) |
-26.43% | Details | |
| 3/5/2024 | Nektar Therapeutics | NKTR | Maintain | Hold (Hold) |
|
Details | ||
| 1/12/2024 | Kura Oncology | KURA | Maintain | Buy (N/A) |
|
Details | ||
| 1/10/2024 | Aclaris Therapeutis | ACRS | Downgrade | Hold (Buy) |
1.28 (1.23) |
-3.91% | Details | |
| 12/15/2023 | Aclaris Therapeutis | ACRS | Maintain | Buy (N/A) |
|
Details | ||
| 12/15/2023 | Aadi Bioscience Inc | AADI | Maintain | Buy (N/A) |
|
Details | ||
| 12/15/2023 | Acrivon Therapeutics Inc | ACRV | New Coverage | Buy (N/A) |
5.20 (10.54) |
102.69% | Details | |
| 12/15/2023 | Tourmaline Bio | TRML | New Coverage | Buy (N/A) |
18.55 (15.66) |
-15.58% | Details | |
| 12/12/2023 | Icosavax Inc. | ICVX | Downgrade | Hold (Buy) |
10.49 (15.31) |
45.95% | Details | |
| 11/10/2023 | Inovio Pharmaceuticals | INO | Maintain | Hold (N/A) |
|
Details | ||
| 10/3/2023 | Structure Therapeutics | GPCR | Maintain | Buy (N/A) |
|
Details | ||
| 9/29/2023 | Structure Therapeutics | GPCR | Maintain | Buy (N/A) |
|
Details | ||
| 9/19/2023 | Kinnate Biopharma | KNTE | Maintain | Buy (N/A) |
|
Details | ||
| 6/28/2023 | Protagonist Therapeutics | PTGX | Maintain | Buy (N/A) |
|
Details | ||
| 6/26/2023 | TG Therapeutics | TGTX | New Coverage | Buy (N/A) |
23.60 (13.99) |
-40.72% | Details | |
| 6/26/2023 | Protagonist Therapeutics | PTGX | Maintain | Buy (N/A) |
|
Details | ||
| 6/15/2023 | Lava Therapeutics NV | LVTX | Maintain | Buy (N/A) |
|
Details | ||
| 5/25/2023 | Magma Design | LAVA | New Coverage | Buy (N/A) |
7.34 (7.34) |
0% | Details | |
| 5/25/2023 | Omega Therapeutics | OMGA | New Coverage | Buy (N/A) |
9.66 (2.42) |
-74.95% | Details | |
| 5/25/2023 | Protagonist Therapeutics | PTGX | New Coverage | Buy (N/A) |
25.20 (25.22) |
0.08% | Details | |
| 5/25/2023 | Lava Therapeutics NV | LVTX | New Coverage | Buy (N/A) |
1.88 (2.83) |
50.53% | Details | |
| 5/25/2023 | IO Biotech | IOBT | New Coverage | Buy (N/A) |
2.08 (1.47) |
-29.33% | Details | |
| 5/25/2023 | Structure Therapeutics | GPCR | New Coverage | Buy (N/A) |
26.59 (36.18) |
36.07% | Details | |
| 5/10/2023 | Nektar Therapeutics | NKTR | Upgrade | Hold (Underperform) |
0.77 (1.32) |
71.43% | Details | |
| 3/31/2023 | IGM Biosciences | IGMS | Maintain | Buy (N/A) |
|
Details | ||
| 3/29/2023 | Aadi Bioscience Inc | AADI | Maintain | Buy (N/A) |
|
Details | ||
| 2/28/2023 | Aclaris Therapeutis | ACRS | Maintain | Buy (N/A) |
|
Details | ||
| 2/27/2023 | Kinnate Biopharma | KNTE | Maintain | Buy (N/A) |
|
Details | ||
| 2/24/2023 | Nektar Therapeutics | NKTR | Downgrade | Underperform (Hold) |
3.01 (1.32) |
-56.15% | Details | |
| 2/13/2023 | Glycomimetics | GLYC | Maintain | Buy (N/A) |
|
Details | ||
| 2/10/2023 | Glycomimetics | GLYC | Maintain | Buy (N/A) |
|
Details | ||
| 11/9/2022 | IGM Biosciences | IGMS | New Coverage | Buy (N/A) |
17.20 (7.41) |
-56.92% | Details | |
| 11/8/2022 | Vaxcyte | PCVX | Maintain | Buy (N/A) |
|
Details | ||
| 10/11/2022 | Novavax | NVAX | Maintain | Buy (N/A) |
|
Details | ||
| 8/31/2022 | Altimmune | ALT | Maintain | Buy (N/A) |
|
Details | ||
| 8/16/2022 | Icosavax Inc. | ICVX | Maintain | Buy (N/A) |
|
Details | ||
| 7/29/2022 | Prelude Therapeutics | PRLD | New Coverage | Buy (N/A) |
5.89 (3.44) |
-41.6% | Details | |
| 7/7/2022 | CytomX Therapeutics | CTMX | Downgrade | Hold (Buy) |
1.97 (1.73) |
-12.18% | Details | |
| 5/31/2022 | Nektar Therapeutics | NKTR | New Coverage | Hold (N/A) |
3.54 (1.32) |
-62.71% | Details | |
| 4/28/2022 | Glycomimetics | GLYC | Maintain | Buy (N/A) |
|
Details | ||
| 4/19/2022 | Novavax | NVAX | Maintain | Buy (N/A) |
|
Details | ||
| 4/4/2022 | Finch Therapeutics Group Inc. | FNCH | Maintain | Buy (N/A) |
|
Details | ||
| 3/31/2022 | Replimune Group | REPL | Maintain | Buy (N/A) |
|
Details | ||
| 3/22/2022 | Icosavax Inc. | ICVX | Maintain | Buy (N/A) |
|
Details | ||
| 2/22/2022 | Novavax | NVAX | New Coverage | Buy (N/A) |
81.89 (3.89) |
-95.25% | Details | |
| 2/15/2022 | Kura Oncology | KURA | New Coverage | Buy (N/A) |
12.90 (17.68) |
37.05% | Details | |
| 1/11/2022 | Aadi Bioscience Inc | AADI | New Coverage | Buy (N/A) |
21.75 (1.80) |
-91.72% | Details | |
| 12/29/2021 | Inovio Pharmaceuticals | INO | New Coverage | Hold (N/A) |
5.72 (10.20) |
78.32% | Details | |
| 12/29/2021 | Vaxart Inc. | VXRT | New Coverage | Buy (N/A) |
6.69 (0.84) |
-87.44% | Details | |
| 12/29/2021 | VBI Vaccines | VBIV | New Coverage | Buy (N/A) |
2.31 (0.63) |
-72.73% | Details | |
| 12/29/2021 | Vaxxinity | VAXX | New Coverage | Buy (N/A) |
6.37 (0.46) |
-92.78% | Details | |
| 12/29/2021 | Vaxcyte | PCVX | New Coverage | Buy (N/A) |
23.09 (60.62) |
162.54% | Details | |
| 12/29/2021 | Icosavax Inc. | ICVX | New Coverage | Buy (N/A) |
22.51 (15.31) |
-31.99% | Details | |
| 12/29/2021 | Metacrine Inc. | MTCR | New Coverage | Hold (N/A) |
0.66 (0.49) |
-25.76% | Details | |
| 12/29/2021 | Altimmune | ALT | New Coverage | Buy (N/A) |
8.84 (6.89) |
-22.06% | Details | |
| 12/1/2021 | Corvus Pharmaceuticals | CRVS | New Coverage | Buy (N/A) |
3.45 (1.41) |
-59.13% | Details | |
| 11/12/2021 | Glycomimetics | GLYC | Upgrade | Buy (Hold) |
2.02 (2.16) |
6.93% | Details | |
| 9/27/2021 | Kinnate Biopharma | KNTE | New Coverage | Buy (N/A) |
23.15 (2.65) |
-88.55% | Details | |
| 9/23/2021 | Aclaris Therapeutis | ACRS | Maintain | Buy (N/A) |
|
Details | ||
| 8/30/2021 | Aclaris Therapeutis | ACRS | Maintain | Buy (N/A) |
|
Details | ||
| 7/23/2021 | Aclaris Therapeutis | ACRS | New Coverage | Buy (N/A) |
15.61 (1.23) |
-92.12% | Details | |
| 7/1/2021 | Atreca Inc. | BCEL | Maintain | Buy (N/A) |
|
Details | ||
| 5/18/2021 | Pieris Pharmaceuticals | PIRS | New Coverage | Buy (N/A) |
1.88 (0.16) |
-91.49% | Details | |
| 5/18/2021 | Equillium | EQ | New Coverage | Buy (N/A) |
5.42 (1.73) |
-68.08% | Details | |
| 4/29/2021 | Cara Therapeutics | CARA | Maintain | Buy (N/A) |
|
Details | ||
| 4/13/2021 | Finch Therapeutics Group Inc. | FNCH | New Coverage | Buy (N/A) |
17.18 (2.36) |
-86.26% | Details | |
| 4/5/2021 | Molecular Templates | MTEM | Maintain | Buy (N/A) |
|
Details | ||
| 3/23/2021 | CytomX Therapeutics | CTMX | Upgrade | Buy (Hold) |
8.52 (1.73) |
-79.69% | Details | |
| 2/8/2021 | Atreca Inc. | BCEL | New Coverage | Buy (N/A) |
14.93 (0.15) |
-99% | Details | |
| 11/2/2020 | Replimune Group | REPL | New Coverage | Buy (N/A) |
43.18 (6.97) |
-83.86% | Details | |
| 9/8/2020 | Molecular Templates | MTEM | New Coverage | Buy (N/A) |
10.26 (1.49) |
-85.48% | Details | |
| 9/2/2020 | Sutro Biopharma | STRO | New Coverage | Buy (N/A) |
10.01 (3.77) |
-62.34% | Details | |
| 8/5/2019 | Glycomimetics | GLYC | New Coverage | Hold (Buy) |
9.13 (2.16) |
-76.34% | Details | |
| 1/3/2019 | Aevi | GNMX | Maintain | Hold (N/A) |
|
Details | ||
| 11/2/2018 | Amarin Corporation | AMRN | Maintain | Buy (N/A) |
|
Details | ||
| 10/15/2018 | AcelRx Pharmaceuticals | ACRX | Upgrade | Buy (Hold) |
3.98 (0.86) |
-78.39% | Details |
